Datapoint: Lilly Scores First-Ever Alopecia Areata Nod

With this week’s FDA approval, Eli Lilly and Incyte’s Olumiant is first-ever treatment for alopecia areata, an autoimmune disease that causes a severe form of hair loss. The JAK inhibitor was first approved in 2018 as a rheumatoid arthritis therapy. For the treatment of rheumatoid arthritis, Olumiant holds covered or better status for 61% of all insured lives. Just 11% of insured lives have preferred access to Olumiant.

SOURCE: MMIT Analytics, as of 6/15/22

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 15

Datapoint: Pfizer Scores Another Hemophilia Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today